Novartis AG vs Vanguard Short Term Corporate Bond ETF — how do they compare? Novartis AG trades at $152.38 (market cap $295.37B), while Vanguard Short Term Corporate Bond ETF trades at $78.52. The key difference: Novartis AG pays a 3.07% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Novartis AG is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| NVS | VCSH | |
|---|---|---|
Market Cap | $295.37B | — |
Sector | Health | Fixed Income |
52-Week High | $168.62 | $80.20 |
52-Week Low | $119.31 | $78.41 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | — |
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →